Paper Details

  1. Home
  2. Paper Details

Preparation and in vitro evaluation of pyridostigmine bromide microparticles.

Author: DemirelMüzeyyen, HegazyNahed, YazanYasemin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the development of microparticles to deliver pyridostigmine bromide (PB), an anticholinesterase agent, for the treatment of myasthenia gravis. The study found that drug release from microparticles could be modified and that the frequent dosage and side effects of pure PB may be reduced with the formulation of microparticles.
Paper Details　
Original Abstract of the Article :
Pyridostigmine bromide (PB) is an anticholinesterase agent whose aqueous solubility is high and which has a short elimination half-life. Its dosage rate in the treatment of myastenia gravis is frequent due to the short half-life and it exhibits side effects. Microparticles designed to deliver a phar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0378-5173(02)00146-1

データ提供：米国国立医学図書館（NLM）

Optimizing the Delivery of Pyridostigmine Bromide: A Microparticle Approach

The world of drug delivery is constantly evolving, searching for ways to enhance therapeutic effectiveness while minimizing side effects. This study delves into the realm of pharmaceutical engineering, exploring the potential of microparticles to improve the delivery of pyridostigmine bromide (PB), an anticholinesterase agent used in the treatment of myasthenia gravis. The researchers utilized an acrylic polymer (Eudragit) to create microparticles, incorporating PB into the formulation. They meticulously investigated the physical characteristics of the microparticles, including their shape, size distribution, and drug release profile.

Tailoring Drug Delivery for Improved Outcomes

Their findings demonstrated that the microparticle formulation could effectively modify the release rate of PB, with the shape of the microparticles playing a key role in controlling drug release. The study suggests that this novel delivery approach could lead to reduced dosage frequency and potentially mitigate the side effects associated with PB administration.

Harnessing the Power of Microparticles in Drug Delivery

The researchers' innovative approach to drug delivery using microparticles presents a promising avenue for optimizing the therapeutic efficacy of PB. This technology could potentially enhance patient compliance and improve the overall treatment experience for individuals with myasthenia gravis.

Dr.Camel's Conclusion

This study showcases the potential of microparticle technology to revolutionize drug delivery systems, offering a more efficient and targeted approach to medication administration. The ability to fine-tune drug release profiles using microparticles could lead to significant improvements in patient outcomes and overall health.

Date :
  1. Date Completed 2002-10-22
  2. Date Revised 2019-09-10
Further Info :

Pubmed ID

12176241

DOI: Digital Object Identifier

10.1016/s0378-5173(02)00146-1

Related Literature

Article Analysis
・Side Effects of pyridostigmine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.